The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.

Those showing a minimal response or no response should be taken off it - with all drug costs refunded by the manufacturer, Janssen-Cilag.

Click here for the NICE release